Mark Altmeyer

Biography

Mr. Mark Altmeyer is the Chief Commercial Officer of Axovant Sciences GmbH and joined the company in March 2015. He has three decades of experience leading successful drug commercialization efforts as a pharmaceutical executive, with a particular focus on therapies for central nervous system disorders. Previously, he served as Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc., where he led 1,700 employees and grew total revenues from $2.6 billion to over $5 billion. He led the launch of Abilify®, the top-selling CNS drug in history and the number one selling drug in the United States in 2013. Earlier in his career, he held a number of executive leadership roles at Bristol-Myers Squibb including senior vice president, Global Commercialization, and senior vice president, Neuroscience Business Unit. He received an MBA from Harvard Business School and a BA from Middlebury College.

Research Interest

neurology, CNS drugs, Alzheimer’s disease and dementia, Balance Impairments, REM Sleep Behavior Disorder, biopharmaceuticals, biology, neuroscience.